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ABSTRACT
Cytosolic DNA sensors are a subgroup of pattern recognition receptors (PRRs) 
and are activated by the abnormal presence of the DNA in the cytosol. Their activation 
leads to the upregulation of pro-inflammatory cytokines and chemokines and can also 
induce cell death. The presence of cytosolic DNA sensors and inflammatory cytokines 
in TS/A murine mammary adenocarcinoma and WEHI 164 fibrosarcoma cells was 
demonstrated using real time reverse transcription polymerase chain reaction (RT-
PCR), western blotting and enzyme-linked immunosorbent assay (ELISA). After 
electrotransfer of plasmid DNA (pDNA) using two pulse protocols, the upregulation 
of DNA-depended activator of interferon regulatory factor or Z-DNA binding protein 
1 (DAI/ZBP1), DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 (DDX60) and interferon-
inducible protein 204 (p204) mRNAs was observed in both tumor cell lines, but 
their expression was pulse protocol dependent. A decrease in cell survival was 
also observed; it was cell type, DNA concentration and pulse protocol dependent. 
Furthermore, the different protocols of electrotransfer led to different cell death 
outcomes, necrosis and apoptosis, as indicated by an annexin V and 7AAD assays. 
The obtained data provide new insights on the presence of cytosolic DNA sensors in 
tumor cells and the activation of different types of cells death after electrotransfer 
of pDNA. These observations have important implications on the planning of gene 
therapy or DNA vaccination protocols.
www.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 27), pp: 18665-18681
INTRODUCTION
Electroporation (EP) is a delivery method in which 
cells are exposed to electric pulses with specific intensities 
and durations in order to increase the permeability of the 
cell membrane, enabling transition of polar molecules 
into the cells. In biomedicine, this technique is widely 
used to transform bacteria and transfect eukaryotic cells 
and tissues [1]. Furthermore, this technique has reached 
clinical applications. In oncology, EP is used clinically 
to facilitate the entry of the chemotherapeutic agents 
bleomycin and cisplatin into the cells of several tumor 
types (electrochemotherapy or ECT), resulting in increased 
antitumor effectiveness of chemotherapeutic drugs leading 
to high percentage of complete tumor regressions [2–6]. 
Currently, ECT is performed in more than 140 cancer 
centers in Europe and is included in the national guidelines 
for treatment in UK, Germany, Slovenia and other EU 
countries. Another application of electroporation that 
has reached clinical trials is gene electrotransfer, where 
electroporation is used for transfection of cells within 
tissues with plasmid DNA (pDNA), generally for the 
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purpose of cancer therapy, cancer vaccines, or infectious 
disease vaccines. In oncology, several clinical trials are 
ongoing for several types of cancer using pDNA encoding 
different therapeutic molecules, either immunomodulatory 
molecules such as interleukin-12 [7] or tumor associated 
antigens [8–11].
Although EP is used clinically, the electrical 
parameters for gene electrotransfer differ substantially 
depending on the therapeutic use. Tissue type, local 
or systemic type of expression as well as its duration, 
which are crucial for successful treatment outcomes, also 
affect the choice of electrical parameters for effective 
gene transfer. Currently, no universal pulse protocol 
exists for specific tissue applications, although three 
primary pulse protocols are used for tissue transfection. 
In the first, the same electrical parameters are used as 
in electrochemotherapy [12]. Plasmid delivery with this 
pulse protocol has reached tumor targeted clinical trials in 
the United States for melanoma [7], Merkel cell carcinoma 
[13], squamous cell carcinoma, and triple-negative breast 
cancer (ClinicalTrials.gov). In the second, electric pulses 
of lower amplitude and longer duration are used [14, 15]. 
This pulse type has reached clinical trials for muscle 
delivery [8]. Finally, a combination of high voltage and 
low voltage electric pulses can be utilized [16, 17]. This 
combination of pulse types has reached clinical trials for 
intratumor delivery [18].
At the cellular level, the mechanisms of 
electrotransfer-mediated pDNA entry are not fully 
understood. After the exposure of the cell to electric pulses 
in the presence of pDNA, a DNA-membrane complex is 
formed on the membrane facing the cathode [19, 20], 
then this complex enters the cells via endocytosis [21] or 
macropinocytosis [22]. DNA escapes intracellular vesicles 
to enter the cell’s nucleus to be transcribed then translated 
into the therapeutic protein. Only DNA that enters the cells 
via these mechanisms is transcribed, because inhibitors of 
endocytosis almost completely abrogate the expression of 
pDNA-encoded genes [23, 24]. 
In our previous study, we showed that the mRNAs 
and proteins of the receptors of the innate immune system 
that recognize foreign DNA (cytosolic DNA sensors) 
were upregulated after vector pDNA (plasmid backbone 
without therapeutic gene) electrotransfer in B16F10 
melanoma cells [25]. This indicated that DNA is detected 
in the cytosol after endosomal escape or hypothetically 
it may also enter directly via electropores formed in the 
cell membrane [26–28]. Cytosolic DNA sensors are a 
subgroup of pattern recognition receptors (PRRs) and 
are activated by the abnormal presence of the DNA in 
the cytosol. Their activation leads to the upregulation 
of pro-inflammatory cytokines and chemokines, which 
may induce and inflammatory immune response. This 
activation can also lead to cell death [29–33]. In addition 
to upregulation of several cytosolic DNA sensors, in our 
previous studies, we showed increased cell death in vitro 
and complete regression of tumors in vivo [34, 35]. These 
effects were accompanied by increased production of 
interferon β (IFNβ) both in vitro and in vivo implicating 
paracrine-autocrine signaling leading to cell death [25].
Tumor regression and increased cell death in vitro 
have been demonstrated for other tumors such as sarcomas 
and carcinomas, and for tumor cell lines, following 
electrotransfer of pDNA devoid of therapeutic genes 
[36–45]. However, it is not known whether other tumor 
cell types of mesoderm origin (fibrosarcoma) and ectoderm 
origin (carcinoma) respond to pDNA electrotransfer in a 
manner similar to melanoma cells. Because the activation of 
immune system is important for planning and developing new 
treatment modalities for cancer, three different types of DNA 
electrotransfer pulse protocols were evaluated for potential 
upregulation of cytosolic DNA sensors and the downstream 
consequences of their activation, such as the production of 
pro-inflammatory molecules and induced cell death.
RESULTS
Transfection efficiency, cytotoxicity and ATP 
levels
Transfection efficiency, cell survival, and ATP 
levels were quantified after electrotransfer into TS/A and 
WEHI 164 cells using three different pulse protocols. The 
number of transfected cells, or transfection efficiency, was 
pulse protocol dependent. Pulse protocol EP2 produced 
a significantly higher transfection efficiency in both 
cell lines than the other pulse protocols, with 39.7 ± 
4.8% fluorescent cells in TS/A cell line and 74.9 ± 0.8% 
in WEHI 164. Both the EP1 and EP3 pulse protocols 
transfected less than 10% of cells (Figure 1). 
Although the transfection efficiency varied greatly 
between the pulse protocols, in TS/A cells no statistically 
significant changes in median fluorescence intensity 
between pulse protocols were observed.  Whereas, in 
WEHI 164 cells, the fluorescence intensity of cells 
following transfection with the EP1 pulse protocol was 
statistically significantly higher than fluorescence intensity 
of cells transfected with the other two pulse protocols, 
indicating that although this pulse protocol is very 
cytotoxic (Figure 2), it enables higher numbers of plasmid 
copies to enter the cell’s nucleus for expression. 
The EP1 pulse protocol was less cytotoxic to TS/A 
cells (Figure 2A) than to WEHI 164 cells (Figure 2B); 
the application of EP1 pulses alone decreased the survival 
fraction by 49% in TS/A cells and 67% in WEHI 164 
cells. Cell survival was less affected in either cell line after 
application of pulse protocols EP2 or EP3 alone (Figure 
2A, 2B).  For pulse protocols EP1 and EP2, the addition of 
pDNA further decreased cell viability in a dose-dependent 
manner that was particularly detectable in WEHI 164 cells 
(Figure 2B). On the other hand, the addition of pDNA had 
no effect on cell survival after the application of the EP3 
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pulse protocol; therefore, this protocol was not tested in 
subsequent experiments.
Thirty minutes after gWiz Blank electrotransfer 
with EP1 and EP2, ATP levels were measured (Figure 2C, 
2D, Supplementary Table 2) to determine if the observed 
difference in the cytotoxic effects between electrotransfer 
pulse protocols was due to ATP leakage, which can cause 
cell necrosis.
A significant decrease in ATP levels was observed after 
pulse delivery. The decrease after EP1 pulse delivery alone 
was significantly greater than the decrease after EP2 pulses 
alone. The addition of pDNA further reduced ATP levels in 
cells using EP1 but not EP2 for delivery of pDNA (p < 0.05). 
Cell death mechanisms and morphology
We investigated the mechanisms of cell death using 
pulse protocols EP1 and EP2. Differences in the level 
of apoptosis (early apoptosis) or necrosis (accompanied 
by late apoptosis) depended on the cell line and the 
electrotransfer protocol. In TS/A cells, both necrotic and 
apoptotic cells were detected with both EP pulse protocols 
20 hours after electrotransfer of pDNA (Figure 2E); cell 
death was higher after EP1 pulses (Figure 2A). In WEHI 
164 cells, we observed a greater number of apoptotic cells 
after pDNA electrotransfer using pulse protocol EP2 (p < 
0.05), and a greater number of necrotic cells after pDNA 
electrotransfer using pulse protocol EP1 (p < 0.05) (Figure 
2F). These results were confirmed morphologically using 
Giemsa staining perfomed 6 hours after electrotranfer of 
pDNA (Supplementary Figures 1, 2). Several necrotic cells 
were observed after electrotransfer of pDNA using pulse 
protocol EP1 in both cell lines. Based on Giemsa staining, 
we confirmed that a greater quantity of apoptotic cells were 
produced after electrotransfer using the EP2 pulse protocol 
in WEHI 164 cells. 
Figure 1: Transfection efficiency of TS/A and WEHI 164 cell lines after pEGFP-N1 electrotransfer using three different 
pulse protocols of DNA electrotransfer. pEGFP-N1 was electrotransfered by delivery of eight 5 ms pulses with a voltage to distance 
ratio of 600 V/cm, frequency 1 Hz (EP1), six 100 µs pulses with a voltage to distance ratio of 1300 V/cm, frequency 4 Hz (EP2) or with 
combination of one 100 µs pulse with a voltage to distance ratio 600 V/cm and four 100 ms pulses with a voltage to distance ratio 80 V/
cm, duration, frequency 1Hz (EP3) using plate electrode. *statistically significant difference of percentage of fluorescent cells between 
electrotransfer protocol groups (P < 0.05). †Statistically significant difference between the mean values of median fluorescence intensity of 
cells receiving the EP1 protocol and fluorescence intensity of cells receiving the EP2 and EP3 pulse protocols.
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Increased expression of DNA sensors depends on 
pulse protocol selection and cell type
The mRNAs for several PRRs were detected in 
both TS/A (Table 1) and WEHI 164 cells (Table 2), while 
the mRNAs for toll-like receptor 9 (TLR9), retinoic 
acid inducible gene I (RIG1), and absent in melanoma 2 
(AIM2) were not. SRY box 2 (SOX2) mRNA was detected 
in WEHI 164 but not TS/A cells. After vector pDNA 
electrotransfer, several DNA sensors were upregulated at 
the mRNA level. Increased expression of DDX60, DAI/
ZBP1 and p204 mRNAs occurred in both cell lines with 
variation in the level of expression depending on the 
cell line and the EP pulse protocol used (Tables 1, 2). 
There were, however, differences between cell lines. 
DEAH (Asp-Glu-Ala-His) box helicase 36 (DHX36) 
was significantly upregulated in TS/A cells after pDNA 
delivery with EP1. The mRNAs for leucine-rich repeat 
flightless-interacting protein 1 (LRRFIP1), interferon 
activated gene 202 (p202), and p204 were minimally but 
significantly upregulated after pDNA delivery with EP2 
in WEHI 164 cells. 
Figure 2: Cell survival, ATP level determination and cell death mechanism after electrotransfer in TS/A and WEHI 164 
cell lines. Cell survival was measured 72 hours after electrotransfer of pDNA using the pulse protocols described in methods and Figure 
1 in (A) TS/A cells and (B) WEHI 164 cells. The survival fraction was normalized to an unexposed control group. The concentrations on 
X-axis represent  final pDNA concentrations; 10 µg/106 cells, 20 µg/106 cells and 35 µg/106 cells in 50 µl of total volume, respectively. The 
percentage of ATP inside (C) TS/A and (D) WEHI 164 cells was determined immediately after electrotransfer. Cell death mechanisms were 
quantified in (E) TS/A and cells (F) WEHI 164 cells for the EP1 and EP2 electrotransfer protocols in the presence and absence of pDNA 
by flow cytometry for Annexin V and 7-AAD. *Statistically significant difference compared to different electrotransfer pulse protocol (EP) 
groups (P < 0.05). †statistically significant difference between indicated groups (P < 0.05). #statistically significant difference from pDNA 
group (p < 0.05).
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Table 1: Fold changes in mRNA levels of endosomal and cytosolic DNA sensors in TS/A tumor cells 4 hours after pDNA 
electrotransfer
TS/A control gWiz Blank EP1 EP2 EP3 pDNA+EP1 pDNA+EP2 pDNA+EP3
n foldex ± SE n foldex ± SE n foldex ± SE n foldex ± SE n foldex ± SE n foldex ± SE n foldex ± SE n foldex ± SE
TLR9 8 / 6 / 3 / 2 / 3 / 4 / 3 / 3 /
RIG-1 8 / 6 / 3 / 2 / 3 / 4 / 3 / 3 /
DDX60 9 1.2 ± 0.3 6 0.7 ± 0.3 4 0.7 ± 0.2 2 1.7 ± 1.2 3 0.8 ± 0.0 7 3.2 ± 0.7* 5 4.0 ± 0.9* 3 1.0 ± 0.2
DHX9 8 1.2 ± 0.2 6 0.3 ± 0.1 4 0.4 ± 0.1 2 1.7 ± 1.2 3 1.3 ± 0.2 4 0.1 ± 0.0 3 1.4 ± 0.3 3 0.8 ± 0.1
DHX36 9 1.3± 0.4 6 0.6± 0.1 4 0.9 ± 0.3 2 1.7 ± 1.2 3 0.9 ± 0.1 4 7.7 ± 1.2* 5 1.9 ± 1.0 3 0.6 ± 0.1
AIM 8 / 5 / 3 / 2 / 3 / 3 / 3 / 3 /
cGAS 7 1.4 ± 0.5 5 1.1 ± 0.3 3 1.0 ± 0.4 2 1.9 ± 1.1 3 1.7 ± 0.1 3 1.6 ± 0.6 3 1.0 ± 0.1 3 1.1 ± 0.1
DAI/ZBP1 8 1.7 ± 0.5 4 1.5 ± 1.2 3 0.7 ± 0.1 2 1.7 ± 1.2 3 1.1 ± 0.2 5 14.1 ± 3.9* 3 3.0 ± 0.6* 3 1.0 ±0.1
DDX41 6 1.1 ± 0.2 4 1.3 ± 0.2 3 1.6 ± 0.4 2 1.8 ± 1.1 3 1.2 ± 0.2 3 1.3 ± 0.5 3 1.3 ± 0.2 3 0.9 ± 0.0
LRRFIP1 6 0.8 ± 0.1 5 0.8 ± 0.1 3 1.1 ± 0.2 2 1.8 ± 1.1 3 1.2 ± 0.1 3 2.2 ± 0.8 3 2.8 ± 1.2 3 0.9 ± 0.0
P202 7 1.2 ± 0.2 5 0.8 ± 0.3 3 0.7 ± 0.3 2 1.7 ± 1.2 3 0.9 ± 0.0 3 2.8 ± 1.0 3 4.1 ± 2.4 3 1.0 ± 0.1
P204 3 1.0 ± 0.2 2 1.0 ± 0.1 2 0.6 ± 0.1 2 1.9 ± 0.5 3 1.2 ± 0.1 3 1.1 ± 0.1 3 3.4 ± 0.3* 3 2.1 ± 0.2*
SOX2 4 / 2 / / 2 / 2 / 3 / 3 / 2 /
MRE1 4 1.2 ± 0.2 2 1.5 ± 0.4 2 0.8 ± 0.1 2 1.0 ± 0.1 2 0.6 ± 0.0 3 0.8 ± 0.2 3 0.9 ± 0.1 2 0.5 ± 0.0
Ku70 4 0.9 ± 0.2 2 1.0 ± 0.1 2 1.1 ± 0.0 2 0.8 ± 0.1 2 1.0 ± 0.0 3 1.0 ± 0.1 3 0.8 ± 0.1 2 1.0 ± 0.0
Legend: cGAS, cyclic guanosine monophosphate-adenosine monophosphate synthase; DAI/ZBP1, DNA-dependent activator of interferon regulatory factor; DDX41, DEAD (Asp-Glu-Ala-Asp) box polypeptide 
41; DDX60, DEAD (Asp-Glu-Ala-Asp) box polypeptide 60; DHX9, DEAH (Asp-Glu-Ala-His)box helicase 9; DHX36, DEAH (Asp-Glu-Ala-His) box helicase 36; LRRFIP1, leucine-rich repeat flightless-
interacting protein 1; p204, interferon activated gene 204; p202, interferon activated gene 202; MRE11, meiotic recombination 11 homolog, double strand break repair nuclease; SOX2, SRY (sex determining 
region Y)-box 2; Ku70, Lupus Ku autoantigen protein p70*statistically significant difference compared to control group (P < 0.05); ND, not detected.
Table 2: Fold changes in mRNA levels of endosomal and cytosolic DNA sensors in WEHI 164 tumor cells 4 hours after 
pDNA electrotransfer
WEHI 164 control gWiz Blank EP 1 EP 2 EP 3 pDNA+EP1 pDNA+EP2 pDNA+EP3
n foldex ± SE n foldex ± SE n foldex ± SE n foldex ± SE n foldex ± SE n foldex ± SE n foldex ± SE n foldex ± SE
TLR9 4 / 3 / 3 / 3 / 3 / 5 / 5 / 3 /
RIG-1 4 / 3 / 3 / 3 / 3 / 5 / 5 / 3 /
DDX60 4 1.0 ± 0.1 3 1.3 ± 0.3 3 1.4 ± 0.2 3 1.0 ± 0.3 3 0.4 ± 0.1 5 16.4 ± 5.4* 5 58.1 ± 22.4* 3 1.9 ± 0.2
DHX9 4 1.1 ± 0.3 3 1.3 ± 0.1 3 1.8 ± 0.4 3 1.6 ± 0.2 3 0.8 ± 0.1 5 2.0 ± 0.3 5 1.0 ± 0.2 3 1.0 ± 0.1
DHX36 4 1.0 ± 0.1 3 1.4 ± 0.5 3 1.9 ± 0.3 3 1.3 ± 0.1 3 0.5 ± 0.2 5 1.0 ± 0.4 5 1.1 ± 0.3 3 0.7 ± 0.1
AIM 4 / 3 / 3 / 3 / 3 / 5 / 5 / 3 /
cGAS 4 1.0 ± 0.1 3 1.1 ± 0.0 3 2.4 ± 0.3 3 1.6 ± 0.1 3 1.0 ± 0.1 5 0.7 ± 0.2 5 1.2 ± 0.4 3 1.9 ± 0.2
DAI/ZBP1 4 1.0 ± 0.2 3 1.4 ± 0.4 3 1.4 ± 0.3 3 1.3 ± 0.1 3 0.5 ± 0.0 5 3.4 ± 0.1* 5 27.2 ± 1.8* 3 3.1 ± 0.3*
DDX41 4 1.0 ± 0.1 3 1.1 ± 0.2 3 1.3 ± 0.2 3 1.1 ± 0.1 3 0.7 ± 0.1 5 1.5 ± 0.3 5 1.4 ± 0.1 3 0.9 ± 0.1
LRRFIP1 4 1.1 ± 0.2 3 1.2 ± 0.3 3 1.8 ± 0.5 3 1.8 ± 0.1 3 0.8 ± 0.1 5 1.5 ± 0.1 5 2.7 ± 0.1* 3 1.0 ± 0.2
P202 4 1.0 ± 0.2 3 1.2 ± 0.2 3 1.5 ± 0.3 3 1.2 ± 0.2 3 0.9 ± 0.1 5 1.7 ± 0.5 5 3.7 ± 0.3* 3 0.9 ± 0.2
P204 3 1.0 ± 0.0 3 1.3 ± 0.2 3 1.0 ± 0.0 3 1.0 ± 0.1 3 1.1 ± 0.1 3 2.5 ± 0.7 3 2.6 ± 0.2* 3 1.3 ± 0.2
SOX2 3 1.0 ± 0.3 3 1.0 ± 0.3 2 1.0 ± 0.3 2 1.4 ± 0.1 2 0.4 ± 0.0 2 0.5 ± 0.1 2 0.5 ± 0.2 2 0.9 ± 0.2
MRE1 3 1.0 ± 0.2 3 0.9 ± 0.2 2 1.8 ± 0.6 2 0.9 ± 0.0 2 0.6 ± 0.0 2 1.1 ± 0.1 2 0.8 ± 0.1 2 1.0 ± 0.1
Ku70 3 1.0 ± 0.2 3 0.9 ± 0.1 2 1.9 ± 0.7 2 0.8 ± 0.1 2 0.8 ± 0.0 2 1.2 ± 0.1 2 0.7 ± 0.1 2 1.2 ± 0.0
Legend: cGAS, cyclic guanosine monophosphate-adenosine monophosphate synthase; DAI/ZBP1, DNA-dependent activator of interferon regulatory factor; DDX41, DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 41; DDX60, DEAD (Asp-Glu-Ala-Asp) box polypeptide 60; DHX9, DEAH (Asp-Glu-Ala-His)box helicase 9; DHX36, DEAH (Asp-Glu-Ala-His) box helicase 36; LRRFIP1, leucine-rich repeat 
flightless-interacting protein 1; p204, interferon activated gene 204; p202, interferon activated gene 202; MRE11, meiotic recombination 11 homolog, double strand break repair nuclease; SOX2, SRY (sex 
determining region Y)-box 2; Ku70, Lupus Ku autoantigen protein p70*statistically significant difference compared to control group (P < 0.05); ND, not detected.
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Our previous study demonstrated that increased 
mRNA expression for particular PRRs can translate into 
increased protein levels in B16F10 melanoma cells in vitro 
[25]. Here, TS/A cells were exposed to electrical pulses 
using the EP1 or EP2 pulse protocols in the presence 
and in the absence of pDNA. When cleared cell lysates 
were analyzed by Western blotting, a significant decrease 
in DAI/ZBP-1 protein expression was observed in the 
EP1+pDNA experimental group (Figure 3A). This was 
quite unexpected, since mRNA levels for this protein were 
the most highly upregulated in this experimental group 
(Table 1).
Previous work from other groups showed that 
DAI/ZBP-1 resides in the cytosol with a diffuse, but 
partially granular-like pattern in HeLa and L929 cells 
[46, 47]. Overexpressed proteins may form inclusion 
bodies that could be eliminated from the cell lysate 
during centrifugation. So, the final step of centrifugation 
was excluded from the lysate preparation protocol 
and, when the crude lysate was analyzed by Western 
blotting, significant upregulation of DAI/ZBP1 protein 
was observed in EP1+pDNA and, to the lesser extent, in 
EP2+ pDNA experimental groups (Figure 3B, 3C).
Increased expression of IFNβ and TNFα after 
electrotransfer
In each group receiving electrotransfer of pDNA, a 
marker for DNA sensor activation, IFNβ, was upregulated 
on the mRNA level in both cell types. (Figure 4A, 4B) In 
TS/A cells, this upregulation of approximately 30-fold was 
comparable between the two pulse protocols (Figure 5A). 
However, this increase was reflected in increased protein 
levels only after pDNA delivery using EP1 (Figure 4C). 
IFNβ upregulation was more marked in WEHI 164 cells 
(Figure 4B). In these cells, the increase in IFNβ protein 
levels, approximately 150-fold, was similar between the 
two pulse protocols (Figure 4D). 
The mRNA of the inflammatory marker TNFα 
was upregulated and increased production of protein 
detected after electrotransfer of pDNA. Specifically, in 
TS/A cells, the increase in mRNA and protein levels were 
observed only after electrotransfer of pDNA using EP1 
pulse protocol (Figure 4A, 4B). In WEHI 164 cells, the 
mRNA of TNFα was upregulated after electrotransfer 
of pDNA with each pulse protocols (Figure 4B); 
however, production of TNFα protein was increased only 
after pDNA electrotransfer using EP1 pulse protocol 
(Figure 4D).
Detection of mRNA IFNβ receptor (IFNAR1) 
and detection of TNFα receptor (TNFR1) by 
Immunohistochemistry in TS/A and WEHI 164 
cell lines
Type I interferon receptors are ubiquitously 
expressed in cells [48], which was confirmed with RT-PCR 
on the mRNA level in both cell lines (data not shown). 
Immunocytochemical staining of cells also confirmed that 
both cell lines express TNFα receptor (Figure 5B).
Figure 3: Changes in DAI/ZBP-1 expression in TS/A cells. Panel (A) shows Western blot analysis of DAI/ZBP1 expression 
among different experimental groups when cell lysate was cleared by centrifugation, while panel (B) shows the analysis of crude cell lysate. 
Panel (C) represents the results of 3 independent experiments (mean ± standard error of the mean, n = 3; open bars represent clear lysate, 
filled ones represent crude lysate;**p < 0.01; *p < 0.05). 
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DISCUSSION
The results of our study demonstrate that, in general, 
different gene electrotransfer pulse protocols that have 
different transfection efficiencies and produce different 
levels of immediate cell death can have similar effect on 
the expression of cytosolic DNA sensors in tumor cell 
lines. Although higher transfection efficiency was obtained 
in WEHI 164 cells, similar sensors (DAI/ZBP1, DDX60 
and p204) were upregulated in two cell lines TS/A and 
WEHI 164 as in our previous study on B16F10 melanoma 
cells [49]. The EP1 protocol produced higher levels of 
IFNβ and TNFα in both cell lines than the EP2 protocol; 
these levels were higher in WEHI 164 than in TS/A cells. 
Finally, cell death can be induced by the electrotransfer 
of pDNA, with apoptosis prevalent in WEHI 164 after 
delivery with the EP2 protocol and necrosis prevalent after 
delivery with the EP1 protocol, while in TS/A cells both 
types of cell death occurred to the same level.  
We initially determined transfection efficiency. 
Delivery with the EP2 pulse protocol led to a high 
percentage of transfected cells of both cell lines, while 
pDNA delivery with the EP1 pulse protocol significantly 
increased only the median fluorescence intensity in 
WEHI 164 cells. This indicated that higher number of 
plasmid copies were introduced into the cells. Both 
types of pulse protocols were previously used in many 
studies in vitro and in vivo  [44, 50–52]. In vivo, in 
B16F10 mouse melanomas and P22 rat carcinomas, both 
pulse protocols yielded similar GFP expression, while 
in other tumor models (T24 human bladder carcinoma, 
SaF mouse sarcoma), the EP1 pulse protocol resulted 
in higher expression [53]. Many parameters pertinent 
to the tumor type, to the tumor microenvironment, to 
the pDNA and to the electrical parameters influence the 
transfection efficiency [17, 54–57]. Previous studies 
using a combination of short, high voltage and long, 
low voltage pulses showed a similar or even greater 
transfection efficiency in vivo in tissues compared to 
electrotransfer with EP1 and EP2 [16, 55, 58, 59]. In 
vitro, the transfection efficiency using EP3 pulse protocol 
in Chinese hamster ovary cells was similar to that obtained 
Figure 4: Effect of different electrotransfer pulse protocols on fold changes in mRNA and protein levels of INFβ and 
TNFα. Levels of IFNβ and TNFα mRNA (A, B) were determined 4 hours after electrotransfer of vector pDNA using the pulse protocols 
described in methods and Figure 1. Intracellular levels of IFNβ and TNFα in the supernatant (C, D) were measured by ELISA 4 hours after 
electrotransfer.*statistically significant difference compared to electrotransfer protocol only (EP) groups (p < 0.05).
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with high voltage alone [66]. In contrast, our results 
showed that this combined pulse protocol was not effective 
for in vitro transfection of WEHI 164 fibrosarcoma 
or TS/A carcinoma cells, although modifications of 
this pulse protocol may be more successful. The EP3 
pulse protocol used in our study had the lowest effect 
on transfection efficiency (<5%), DNA sensor mRNA 
upregulation (<2-fold) and cell survival (>80%) of the 
pulse types tested. This pulse protocol clearly delivers 
DNA more effectively to cells in an in vivo environment 
[16, 58, 60, 61]. In in vivo environments, high voltage 
pulses are crucial for efficient permeabilization of the 
membrane which enables transfection, while low voltage 
pulses provide electrophoretic force to pull negatively 
charged DNA molecules toward the cell membranes 
[58, 60]. This was demonstrated for skin and muscle, 
while for tumors the separation of electrophoretic and 
permeabilization components did not result in improved 
transfection [16, 55]. The same seems true for the selected 
cell lines, since the combination pulse regimen triggered 
only minimal DNA entry into the cell.
The higher transfection efficiency after delivery 
with the EP2 protocol indicated more efficient DNA 
uptake by an endocytosis-like mechanism [21, 22]. In 
TS/A cells, this higher transfection efficiency did not 
correlate with the upregulation of PRR mRNAs; both 
pulse protocols upregulated DDX60 and DAI/ZBP1, 
while the EP1 protocol additionally upregulated DHX36, 
and the EP2 protocol additionally upregulated p204. On 
the other hand, a correlation between higher transfection 
efficiency of EP2 protocol and larger number of 
upregulated cytosolic DNA sensors was obtained in WEHI 
164 cells. Delivery with pulse protocol EP3, combining 
one high voltage pulse with four low voltage pulses, only 
modestly transfected cells, had no effect on cell death and 
only minimally upregulated p204 in TS/A cells and DAI/
ZBP1 in WEHI 164 cells. The possible explanation for 
these observations could be different entry mechanisms 
for pDNA [28]. During electrotransfer, DNA enters the 
cell via an endocytosis-like mechanism [21, 22] but must 
escape the endosomes through the cytosol to the nucleus to 
be expressed. Early endosomal escape from the endosome 
to the nucleus can also occur [26]. Alternatively, DNA may 
be delivered directly to the cytosol through electropores 
formed in the plasma membrane [27, 28]. Thus, due to 
the high transfection efficiency, higher cell survival, and 
pronounced upregulation of DNA sensors, the entry of 
pDNA with EP2 protocol is most probably endocytosis, 
while DNA entry following EP1 is more likely to be 
through electropores, although other groups demonstrated 
that endocytosis occurs after the use of EP1 pulses too 
[21, 22]. 
The pulse protocols used in our study were cytotoxic 
to both cell lines, even in the absence of pDNA. The most 
cytotoxic was EP1 protocol, followed by EP2 protocol, 
while EP3 only minimally reduced cell survival of TS/A 
cells. Nanosecond pulses can directly induce apoptosis 
through activation of mitochondrial signal pathways [62]. 
Alternatively, the destruction of the cell membrane by 
subnanosecond electric pulses can lead to necrosis [63]. 
Electric pulses with appropriate parameters can kill cancer 
cells directly through the induction of apoptosis without 
Figure 5: Immunohistochemistry of TNFR1 receptor in TS/A and WEHI 164 cell line. Cells were fixed with 4% 
paraformaldehyde (A, B). Cells where receptor for TNFα (TNFR1) was present were stained in orange due to the Cy3-conjugated Donkey 
Anti-Rabbit IgG. 
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chemical drugs [64]. In both cell lines, application of 
EP1 pulses were highly cytotoxic even in the absence 
of pDNA. This electrical cell damage is probably due 
to the too high electric fields that cause membrane 
damage resulting in electrolyte imbalance, influx of 
water, osmotic swelling of the cells and consequently 
cell death by necrosis [63, 65, 66]. Molecular dynamics 
simulations of electroporation in several lipid systems 
demonstrated that direct interaction between electric field 
and phospholipids exist [67]. Furthermore, in CHO cells, 
a direct interaction between the movement of membrane 
phosphatidylserine and electric field was demonstrated 
[68]. Thus, we can presume that the induction of necrosis 
following EP1 protocol is a physical process. Interestingly, 
CHO cells retained high viability using this pulse protocol, 
emphasizing the variation between cell lines [69].
Enhanced toxicity of the electric pulses in presence 
of the pDNA was reported in previous studies [70, 71]. In 
support of these observations, the cell death mechanism in 
response to the combination of pulses and DNA was both 
pulse protocol and pDNA dosage dependent (Figure 2), 
which is in agreement with our previous study [72], 
although there are differences in cell survival between 
the cell lines. Apoptosis was the major mechanism of 
cell death using the EP2 pulse protocol, while necrosis 
predominated when using the EP1 pulse protocol in 
WEHI 164 cells. In TS/A cells, both apoptosis and 
necrosis contributed equally to cell death. The cell 
morphology, which was assessed six hours after the 
therapy, demonstrated mainly necrotic cells death, while 
the data obtained by flow cytometry 20 h after therapy, 
demonstrated that both types of cell death occurred. This 
difference is due to the fact that apoptosis is a longer 
process than necrosis.
Cell death can also occur due to the loss of ATP 
after EP [73]. A significant reduction in intracellular ATP 
immediately after EP was demonstrated. This reduction 
was higher after the application of the EP1 pulse protocol 
than after the EP2 protocol. This reduction might indicate 
that more membrane damage was produced using long, 
low voltage pulses (EP1 pulse protocol) than short, high 
voltage pulses (EP2) (Figure 2). However, although the 
ATP loss was significant, it did not correlate with the 
reduction of cell survival, thus the obtained cell death 
could not be a direct consequence of the ATP loss that 
occurred within 30 minutes of electrotransfer. 
The presence of foreign DNA in the cell can be 
detected by DNA sensors located in the cytosol or on 
the endosomal membrane. The activation of cytosolic 
DNA sensors takes place when these sensors detect and 
bind DNA in the cytosol [29–33]. Upon activation, these 
sensors induce the production of cytokines and potentially 
cell death. The upregulation of both endosomal and 
cytosolic DNA sensors was explored in our study. The 
results demonstrate that effective electrotransfer protocols 
have similar effects on the expression of DNA sensors, 
induce a cytokine response and produce cell death in 
vitro. Similar cytosolic DNA sensors were upregulated in 
TS/A murine mammary adenocarcinoma and WEHI 164 
fibrosarcoma cells after effective electrotransfer protocols 
EP1 and EP2, confirming our previous study on B16F10 
melanoma [72]. These results imply that many tumor cell 
types respond similarly to pDNA electrotransfer. 
Although, in general, the basal levels of mRNA 
of the assayed PRRs were higher in TS/A cells, the 
upregulation was more pronounced in WEHI 164 cells 
(data not shown). The upregulation of DAI/ZBP1, DDX60, 
and p204 was detected previously in B16.F10 melanoma 
cells, and this was confirmed in TS/A mammary carcinoma 
cells. Basal levels of p204 mRNA were higher than those 
of DAI/ZBP1 and DDX60; however, the upregulation was 
more dramatic for DAI/ZBP1 and DDX60. This is similar 
to the results obtained by Zhu in Leydig cells, indicating 
that p204 may be the first sensor to respond to presence of 
DNA and that foreign DNA in the cytosol pronouncedly 
increased the expression of additional DNA sensors [74]. 
Interestingly, additional mRNAs were minimally yet 
significantly upregulated in WEHI 164 fibrosarcoma cells. 
Specifically, after delivery with the EP2 pulse protocol, 
LRRFIP1 and p202 were upregulated. Similar to DDX60 
and DAI/ZBP1, these proteins are also known to activate 
IFNβ [75, 76]. Indeed, IFNβ mRNA and protein, markers 
for DNA sensor activation, were upregulated after pDNA 
electrotransfer. Following EP1 delivery, protein levels 
were similar between the cell types, while only WEHI 164 
cells responded to delivery with EP2. Nearly every cell 
type expresses IFN receptor 1, IFNAR1 [48, 77], and as 
expected, both cell types express the mRNA for IFNRA1 
(data not shown). This potentiates the possible autocrine-
paracrine effect, producing cell death.
Furthermore, upregulation of TNFα mRNA was 
observed in TS/A cells after DNA electrotransfer using 
EP1 pulse protocol or in WEHI 164 cells after any DNA 
electrotransfer or at low levels after exposure of cells to 
electric pulses alone. In WEHI 164 cells, mRNA levels 
did not consistently correlate to increased protein. TNFα 
protein was detected in either cell type only after delivery 
with EP1. While mRNA levels can predict protein levels, a 
lack of correlation is common [78].
Upregulation of DAI/ZBP1 mRNA in TS/A cells 
translated into upregulation on the protein level. The 
expression of DAI/ZBP1 was significantly increased after 
pDNA delivery with the EP1 protocol, and, to the lesser 
extent, the EP2 protocol when crude lysate containing 
all the cellular components was analyzed. Unexpectedly, 
the results obtained from cleared lysate containing only 
soluble proteins demonstrated a significant decrease 
of DAI/ZBP1 content after pDNA delivery with EP1 
pulse protocol. These results lead to the suggestion 
that after pDNA delivery with the EP1 pulse protocol, 
which produces the lowest cell survival rate among the 
pulse protocols we applied, DAI/ZBP1 protein becomes 
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so abundant that it forms insoluble inclusion bodies 
as overexpressed proteins do in many cases under 
unfavorable conditions. This suggestion leaves the open 
question of why the amount of DAI/ZBP1 is significantly 
decreased in clear extract after pDNA delivery with the 
EP1 pulse protocol. One possible explanation could be 
that after inclusion body formation, the expression of this 
protein slows, while protein molecules still present in the 
cytoplasm become less abundant due to common protein 
degradation processes. Additional study is required to 
investigate this possibility. 
Upregulation of p204, DAI/ZBP1 and DDX60 
activate signaling pathways that overlap and result in 
cytokine production that can lead to both apoptosis and 
necrosis [29, 79–83] (Figure 6). The cell death after 
electrotransfer of pDNA using the EP1 pulse protocol 
could be a consequence of the production of IFNβ and 
TNFα. TNFα has shown an antitumor effect on tumor 
cells or tumors in combination with other treatments 
[84–88]. Cell lines that possess receptors for INFβ and/
or TNFα and receptor binding can activate necroptosis or 
apoptosis [89, 90]. Necroptosis is a programmed form of 
Figure 6: Possible signaling pathways activated by pDNA electrotransfer of tumor cells.  After electrotransfer, pDNA (red 
circles) primarily enters the cell through endocytosis (blue circles). Plasmid DNA must undergo endosomal escape to enter the cytosol. 
Endosomal escape can occur early in the endocytosis process or later, before pDNA enters the nucleus [21, 26]. pDNA may possibly enter 
the cytosol directly via electropores formed in cell membrane [28]. The presence of pDNA inside the cytosol of different tumor cell lines is 
associated with the upregulation of cytosolic DNA sensors DDX60, DAI/ZBP1 and the p204 [44, 73, 74]. If these cytosolic DNA sensors 
are activated by binding pDNA, the transcription factor interferon regulator factor 3 (IRF3) is transported from the cytosol to the nucleus 
to induce transcription of IFNβ and other genes [29, 47, 82, 98]. The upregulated and secreted IFNβ protein may bind to its cell-surface 
receptor(s) in an autocrine or paracrine fashion, leading to transcription of pro-inflammatory and apoptotic genes. The DNA sensors p204 
and DAI/ZBP1 can activate a signaling pathway which leads to the nuclear translocation of the transcription factor NF-ĸB and consequently 
to transcription of pro-inflammatory cytokines, such as TNFα, which is secreted from the cell [29, 47, 80, 81, 99]. TNFα may bind to 
cell-surface receptors, which leads to the activation of two different death mechanisms (apoptosis or necroptosis) [90]. Another signaling 
pathway of the cytosolic DNA sensor DAI/ZBP1 leads directly to necroptosis through MLKL activation [100]. Cytosolic DNA sensors and 
their signaling pathways described here are present and upregulated in mouse TS/A adenocarcinoma cells, mouse WEHI 164 fibrosarcoma 
cells, and mouse B16F10 melanoma cells [25]. Other DNA sensors, whether upregulated, not upregulated, or as yet undiscovered (labeled 
with “?”) may also influence these signaling pathways.
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necrosis that requires the proteins RIPK3, MLKL, DAI/
ZBP1 and it is induced by death receptors, interferons, 
toll-like receptors, intracellular RNA and DNA sensors 
[91, 92]. Otherwise, the features of necroptosis such as 
disruption of cell membrane and loss of organelles are 
the same as necrosis. Therefore, these death processes 
cannot be morphologically distinguished. To confirm that 
TS/A and WEHI 164 cells might respond in an autocrine 
or paracrine action to the production of IFNβ and TNFα 
proteins, the presence of IFN receptor (IFNAR1) and 
TNFα receptor (TNFR1) were confirmed in both cell 
lines. In TS/A cells, cell death due to the combination of 
apoptosis and necrosis was observed, in WEHI 164 cells, a 
higher level of necrosis was observed after DNA delivery 
with both pulse protocols. Binding of proteins IFNβ and 
TNFα to their receptors could contribute to different cell 
death mechanisms after DNA electrotransfer. 
MATERIALS AND METHODS
Cell lines
TS/A murine mammary adenocarcinoma cells [93] 
were cultured in advanced minimum essential medium 
(AMEM, Gibco, Thermo Fisher Scientific, Waltham, 
MA, USA) supplemented with 5% fetal bovine serum 
(FBS, Gibco) in 5% CO2 humidified atmosphere at 37° C. 
The cell line was tested for authentication in 2017 at 
IDDEx Bioresearch laboratory. WEHI 164 murine 
fibrosarcoma cells (ATCC CRL-1751, American Type 
Culture Collection, Manassas, VA, USA) were cultured in 
Roswell Park Memorial Institute Medium (RPMI-1640, 
Gibco) supplemented with 5% fetal bovine serum (FBS, 
Gibco) in 5% CO2 humidified atmosphere at 37° C.
Plasmids
The vector plasmid gWiz Blank was commercially 
prepared (Aldevron, Fargo, ND, USA) at concentration of 2 
mg/ml in physiological saline. Additionally, concentrations 
of 1 mg/ml by further dilution and 3.5 mg/ml by 
concentration (Concentrator plus, Eppendorf, Hamburg, 
Germany) were prepared. 
Plasmid EGFP-N1 (pEGFP-N1, BD Biosciences, 
San Jose, CA, USA), encoding green fluorescent protein, 
was used for transfection efficiency experiments. It was 
isolated after amplification in a competent Escherichia 
coli (TOP10; Thermo Fisher Scientific) using Maxi-Endo 
Free Plasmid Kits (Qiagen, Hilden, Germany) according 
to the manufacturer’s instructions. The concentration of 
isolated plasmid was measured with Epoch Microplate 
Spectrophotometer (BioTek Instruments, Winooski, VT, 
USA).
DNA Electrotransfer pulse protocols
Cells were prepared and processed as previously 
described [94]. Fifty µL containing 20 µg pDNA per 
1 × 106 cells was pipetted between two electrodes with 
2 mm gap and three different electric pulse protocols 
were applied: EP1 (8 pulses, 600 V/cm, 5 ms duration 
at frequency 1 Hz), EP2 (6 pulses, 1300 V/cm, 100 µs 
duration at frequency 4 Hz) and EP3 (1 pulse 600 V/cm, 
100 µs duration + 4 pulses 80 V/cm, 100 ms duration, 
frequency 1Hz). The cells were then incubated in AMEM 
or RPMI in 6-cm Petri dishes (Corning Incorporated, 
Corning, NY, USA) for determination of transfection 
efficiency, Adenosine triphosphate (ATP) leakage and cell 
death mechanism and in ultralow attachment 6- well or 24-
well plates (Corning Incorporated) for cell survival assays, 
determination of morphological changes and expression of 
DNA sensors and selected cytokine mRNA and protein.
Transfection efficiency 
Two days after electrotransfer with 10 µg 
pEGFP-N1 per 1 × 106 cells, the cells were imaged by 
fluorescence microscopy (Olympus IX-70, Hamburg, 
Germany), then trypsinized and resuspended in 400 µl 
of PBS for flow cytometry analysis (FACSCanto II flow 
cytometer, BD Biosciences). A 488-nm laser (air-cooled, 
20 mW solid state) and 530/30-nm band-pass filter were 
used for the excitation and detection of green fluorescent 
protein fluorescence, respectively. A total of 20,000 
events were measured. The percentage of transfected cells 
represented transfection efficiency, while the fluorescence 
intensity was determined as an indirect measure of the 
amount of pDNA that was introduced into the cells [95].
Cell survival assay
Cell survival was determined 72 hours after 
electrotransfer [96] of 10 µg, 20 µg, and 35 µg gWiz 
Blank per 1 × 106 cells. After electrotransfer, 1 × 103 
cells were incubated in 0.1 ml AMEM in 96-well plates 
(Corning Incorporated) at 37° C in a 5% CO2 humidified 
incubator. The viability of the cells after pulse delivery 
was determined using Presto Blue (Thermo Fisher 
Scientific) per manufacturer’s instructions and normalized 
to the viability of control cells that were not exposed to 
electric field. 
ATP determination assay
Thirty minutes after electrotransfer of gWiz Blank, 
1 × 106 cells were incubated in 1 ml of appropriate media 
for 1h at 37° C at 5% CO2. The cells were centrifuged 
(Heraeus Fresco 21 centrifuge, Thermo Fisher Scientific) 
for 10 minutes at 12000 g. The supernatant was removed, 
and the cell pellets were resuspended in 1 ml of boiling 
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distilled water, vortexed, immediately placed on ice, 
and centrifuged for 5 minutes at 4° C and 21000 g. The 
samples were transferred to the white 96-well plates and 
ATP content was determined (ATP determination kit, 
Molecular Probes, Thermo Fisher Scientific) according to 
manufacturer’s instructions. 
Expression of PRRs and selected cytokines
Four hours after gWiz Blank electrotransfer with 
pulse protocols EP1, EP2 and EP3, total RNA was 
isolated from 1 × 106 cells, cDNA was synthesized and 
diluted 1:10. Relative mRNA levels were determined with 
quantitative RT-PCR using IDT Oligonucleotides (IDT, 
Coralville, IA, USA) (Supplementary Table 1) and Syber 
Select Maste Mix (Thermofisher scientific).
ELISA
Four hours after electrotransfer with gWiz Blank, 
cell cultures were washed with PBS, lysed (Mammalian 
Protein Extraction Buffer, GE Healthcare, Piscataway, NJ, 
USA), and total protein quantified by BCA assays (Pierce 
Biotechnology, Rockford, IL, USA). IFNβ was measured 
by ELISA (PBL Assay Science, Piscataway, NJ, USA) in 
normalized cell culture lysates. Tumor necrosis factor α 
(TNFα) was measured by ELISA (Ray Biotech, Norcross, 
GA, USA) in cell culture supernatants and then normalized 
to the total protein levels in the lysates to account for 
differences in cell number and viability. 
Western blot analysis
TS/A cells were electrotransfected with gWiz Blank 
plasmid as described above using EP1 and EP2 pulse 
protocols. The cells were then seeded into low-attachment 
6-well plates (Corning Incorporated, Corning, NY, USA) 
and incubated for 9 hours. After incubation, the cells 
were lysed using RIPA buffer in accordance with the 
manufacturer’s protocol (Santa Cruz Biotechnology Inc., 
Dallas, TX, USA).  For the preparation of crude lysate, 
the final centrifugation step was excluded. Total protein 
content was determined using a Pierce BCA Protein Assay 
Kit (Fisher Scientific) then adjusted with RIPA buffer. 
Twenty-five µg or 40 µg of total protein (for cleared and 
crude lysate, respectively) per well was separated in a 
10% polyacrylamide gel, transferred onto nitrocellulose 
membrane (Bio-Rad, Hercules, CA), blocked for 1 hour in 
5% milk in TBS Tween-20 buffer (Fisher Scientific) and 
incubated overnight at 4° C with primary antibodies: rabbit 
anti-DAI/ZBP1 or rabbit anti-β-actin as a loading control 
(Fisher Scientific). After washing with TBS Tween-20 
buffer, the membrane was probed with Alexa Fluor 680 
goat anti-rabbit secondary antibody (Fisher Scientific) for 
45 min at room temperature, washed and protein bands 
were visualized with Odyssey Infrared Imaging System 
(LI-COR, Inc., Lincoln, NE, USA). The band intensity 
was quantified using Image J software [97].
Morphological changes of tumor cells after DNA 
electrotransfer 
Six hours after electrotransfer of gWiz Blank, 
1 × 103 cells in 80 μl of PBS were transferred to a slide 
chamber and centrifuge at 123 g for 4 minutes (Cytospin 
2, Thermo Shandon, Runcorn, UK). The slides were air 
dried then stained with Giemsa’s Azure methylene blue 
solution (Merck, Darmstadt, Germany) according to the 
manufacturer’s protocol. Images of cell morphological 
changes were captured with a DP72 CCD camera using 
Olympus BX-51 microscope (Olympus, Tokio, Japan). 
Necrotic cells were characterized as eosinophilic cells 
or as cell ghosts without the presence of nucleus, while 
apoptotic cells characteristics included cytoplasmic 
shrinkage, nuclear condensation, nuclear fragmentation 
and the formation of apoptotic bodies.
Determination of cell death mechanisms
Based on our previous results [49], cell death 
mechanism was determined twenty hours after 
electrotransfer of gWiz Blank by FITC Annexin V 
Apoptosis Detection Kit with 7-AAD (7-Aminoactinomycin 
D) (BioLegend, San Diego, CA, USA) according to 
manufacturer’s instructions for flow cytometric analysis 
(FACSCanto II, BD Biosciences). A total of 20,000 
events were measured. Apoptosis was evaluated by 
phosphatidylserine detection in the outer plasma membrane 
leaflet using Annexin V. Necrotic cells were detected with 
7-AAD, which has a high DNA-binding constant and can 
pass into the nucleus and bind to DNA in necrotic cells.
Immunohistochemistry of TNFR1 receptor
1 × 105 cells were plated in each well of µ-Chamber 
12 well glass slides (Ibidi, Munich, Germany). After 
 24 hours the cells were fixed with 4% paraformaldehyde. 
Then, the cells were stained immunohistochemically 
using primary Anti-TNF Receptor I antibody (Abcam, 
Cambridge, MA, USA) and Cy3-conjugated AffiniPure 
Donkey Anti-Rabbit IgG as a secondary antibody (Jackson 
Immuno Research, PA, USA). 
Statistical analysis
For most experiments, statistical analysis was 
performed by SigmaPlot 12.0 (Systac Software Inc., San 
Jose, CA, USA). Statistical evaluation was made by one-
way analysis of variance (one-way ANOVA). Western blot 
results were analyzed by one-way ANOVA with Holm-
Sidak test. A p-value of less than 0.05 was considered 
statistically significant. ELISA results were analyzed 
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by two-way ANOVA with Tukey-Kramer multiple 
comparisons test (GraphPad Software, La Jolla, CA, 
USA). A p-value less than 0.05 was considered significant.
CONCLUSIONS
We have shown presence of cytosolic DNA sensors 
in different tumor cell lines and the upregulation of several 
sensors after pDNA electrotransfer. This upregulation 
correlates with the expression of IFNβ and TNFα genes 
and proteins. The expression of cytosolic DNA sensors 
is pulse protocol dependent, as is the mechanism of cell 
death. These effects may be due to both electrical cell 
damage, which occurs immediately after application 
of electric pulses, and to the induction of apoptosis or 
necrosis through activation of cytosolic DNA sensors. 
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